Related Experiment Video
Updated: May 28, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B
Yu-Lin Zhou1, Xue-Cai Wang, Yin-Tao Wu
1Dept. of Infection, Yixing People's Hospital, Yixing 214200, China. zhouyl972@163.com
Insights
Adefovir dipivoxil treatment increased HBV specific cellular immunity in chronic hepatitis B patients. HBeAg seroconversion was linked to higher HBV specific CTL levels and potentially influenced by HBV genotypes.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Chronic hepatitis B (CHB) is a persistent viral infection.
- HBeAg seroconversion is a key indicator of treatment response in CHB.
- HBV genotypes and cellular immunity play roles in CHB progression and treatment outcomes.
Purpose of the Study:
- To investigate the relationship between HBeAg seroconversion, HBV genotypes, and HBV specific CTL response.
- To evaluate the efficacy of Adefovir dipivoxil in modulating these factors in CHB patients.
Main Methods:
- Seventy CHB patients with detectable HBV DNA were enrolled.
- Patients received Adefovir dipivoxil (10 mg daily) for 12 months.
- HBV DNA levels, HBeAg status, HBV specific CTL, and HBV genotypes (B and C) were monitored.
Main Results:
- Adefovir dipivoxil treatment significantly increased HBV specific CTL and decreased HBV DNA levels.
- HBeAg seroconversion occurred in 17.78% of patients, with higher CTL levels observed in those who achieved seroconversion.
- HBeAg seroconversion was more frequent in patients with HBV genotype B compared to genotype C.
Conclusions:
- Adefovir dipivoxil enhances HBV specific cellular immunity in CHB patients.
- Increased HBV specific CTL levels are associated with HBeAg seroconversion.
- HBV genotypes may influence the occurrence of HBeAg seroconversion during Adefovir dipivoxil treatment.
Objective:
To explore relationship between HBeAg seroconversion with HBV genotypes and HBV specific CTL in patients with chronic hepatitis B (CHB) treated with Adefovir dipivoxil.
Methods:
Seventy CHB patients had positive HBV DNA (HBV DNA > or = 1 x 10(4) copy/ml), 45 cases had positive HBeAg, of whom 23 cases (51. 11%) had genotype B, 22 cases (48.89%) had genotype C. ALT > 2 x upper limit of normal value (ULN), human leukocyte antigen (HLA)-A(n) positive, patients were treated with Adefovir dipivoxil (commercial name is Mingzheng, Zhengda Tianjing Pharmaceutical Company), 10 mg, orally, once a day. After treatment for 12 months, observe relationship between HBeAg seroconversion with HBV genotypes and HBV specific CTL.
Results:
After treatment with Adefovir dipivoxil for 12 months, HBV specific CTL (0.68% +/- 0.11%) was higher than that before treatment (0.33% +/- 0.11%), t = 8.36 P < 0.001, HBV DNA (3.01 +/- 0.2) log10 copy/ml was lower than that before treatment (6.27 +/- 0.70) log10 copy/ml, t = 12.63 P < 0.001, HBV DNA turned negative (< 500 copy/ml) 43 cases (61.43%), in 45 cases with positive HBeAg, HBeAg turned negative in 13 cases (28.89%), 8 cases had HBeAg seroconversion (17.78%), HBV specific CTL (0.86% +/- 0.05%) of patients with HBeAg seroconversion is higher than (0.61% +/- 0.07%) of patients without HBeAg seroconversion (37 cases, 82.22%) t = 7.88, P < 0.001. In 8 cases with HBeAg seroconversion, 7 cases had genotype B (30.43% of genotype B), 1 cases had genotype C (4.55% of genotype C), chi2 = 5.15, P < 0.05.
Conclusion:
Adefovir dipivoxil can enhance HBV specific cellular immunity of CHB patients. After treatment, occurrence of HBeAg seroconversion is related to increase of HBV specific CTL level and may be related to genotypes.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction